CYPHERPUNK TECHNOLOGIES INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
CYPHERPUNK TECHNOLOGIES INC. (CYPH) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $2.40 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2026-03-16
- CYPHERPUNK TECHNOLOGIES INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2025-03-31 was $2.40, a 13.36% decline year-over-year.
- CYPHERPUNK TECHNOLOGIES INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2024-03-31 was $2.77.
- CYPHERPUNK TECHNOLOGIES INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2020-03-31 was $1.39.
- CYPHERPUNK TECHNOLOGIES INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2025 was $2.40, a 10.45% decline from fiscal 2024.
- CYPHERPUNK TECHNOLOGIES INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2024 was $2.68.
- CYPHERPUNK TECHNOLOGIES INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2021 was $1.55, a 1.31% increase from fiscal 2020.
- CYPHERPUNK TECHNOLOGIES INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2020 was $1.53.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2025-12-31 | $2.40 10-K · filed 2026-03-16 | |||
| 2025-09-30 | $2.40 10-Q · filed 2025-11-12 | |||
| 2025-06-30 | $2.40 10-Q · filed 2025-08-14 | |||
| 2025-03-31 | $2.40 10-Q · filed 2025-05-13 | |||
| 2024-12-31 | $2.68 10-K · filed 2026-03-16 | |||
| 2024-09-30 | $2.77 10-Q · filed 2024-11-13 | |||
| 2024-06-30 | $2.77 10-Q · filed 2024-08-12 | |||
| 2024-03-31 | $2.77 10-Q · filed 2024-05-13 | |||
| 2021-12-31 | $1.55 10-K · filed 2023-03-24 | |||
| 2021-09-30 | $1.55 10-Q · filed 2021-11-12 | |||
| 2021-06-30 | $1.55 10-Q · filed 2021-08-13 | |||
| 2020-12-31 | $1.53 10-K · filed 2022-03-11 | |||
| 2020-09-30 | $1.53 10-Q · filed 2020-11-12 | |||
| 2020-06-30 | $1.53 10-Q · filed 2020-08-13 | |||
| 2020-03-31 | $1.39 10-Q · filed 2020-05-14 | |||
| 2018-12-31 | $5.56 10-K · filed 2020-03-16 | |||
| 2018-09-30 | $5.56 10-Q · filed 2018-11-09 | |||
| 2017-12-31 | $5.55 10-K · filed 2019-04-01 | |||
| 2017-09-30 | $5.55 10-Q · filed 2017-11-13 | |||
| 2017-06-30 | $5.55 10-Q · filed 2017-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |